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STUDY QUESTION:What is known in Europe about the practice of oocyte cryopreservation (OoC), in terms of current statutory back-
ground, funding conditions, indications (medical and ‘non-medical’) and specific number of cycles?
SUMMARY ANSWER: Laws and conditions for OoC vary in Europe, with just over half the responding countries providing this for medical
reasons with state funding, and none providing funding for ‘non-medical’OoC.
WHAT IS ALREADY KNOWN: The practice of OoC is a well-established and increasing practice in some European countries, but data
gathering on storage is not homogeneous, and still sparse for use. Ovarian tissue cryopreservation (OtC) is only practiced and registered in a
few countries.
STUDY DESIGN, SIZE, AND DURATION: A transversal collaborative survey on OoC and OtC, was designed, based on a country
questionnaire containing information on statutory or professional background and practice, as well as available data on ovarian cell and tissue
collection, storage and use. It was performed between January and September 2015.
PARTICIPANTS/MATERIALS, SETTING AND METHODS: All ESHRE European IVF Monitoring (EIM) consortium national coordi-
nators were contacted, as well as members of the ESHRE committee of national representatives, and sent a questionnaire. The form included
national policy and practice details, whether through current existing law or code of practice, criteria for freezing (age, health status), availabil-
ity of funding and the presence of a specific register. The questionnaire also included data on both the number of OoC cycles and cryopre-
served oocytes per year between 2010 and 2014, specifically for egg donation, fertility preservation for medical disease, ‘other medical’
reasons as part of an ART cycle, as well as for ‘non-medical reasons’ or age-related fertility decline. Another question concerning data on
freezing and use of ovarian tissue over 5 years was added and sent after receiving the initial questionnaire.
MAIN RESULTS AND THE ROLE OF CHANCE: Out of 34 EIM members, we received answers regarding OoC regulations and funding
conditions from 27, whilst 17 countries had recorded data for OoC, and 12 for OtC. The specific statutory framework for OoC and OtC var-
ies from absent to a strict frame. A total of 34 705 OoC cycles were reported during the 5-year-period, with a continuous increase.
However, the accurate description of numbers was concentrated on the year 2013 because it was the most complete. In 2013, a total of
9126 aspirations involving OoC were reported from 16 countries. Among the 8885 oocyte aspirations with fully available data, the majority
†ESHRE Pages content is not externally peer reviewed. The manuscript has been approved by the Executive Committee of ESHRE.
© The Author 2017. Published by Oxford University Press on behalf of the European Society of Human Reproduction and Embryology.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits
non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
or 5323 cycles (59.9%) was performed for egg donation, resulting in the highest yield per cycle, with an average of 10.4 oocytes frozen per
cycle. OoC indication was ‘serious disease’ such as cancer in 10.9% of cycles, other medical indications as ‘part of an ART cycle’ in 16.1%,
and a non-medical reason in 13.1%. With regard to the use of OoC, the number of specifically recorded frozen oocyte replacement (FOR)
cycles performed in 2013 for all medical reasons was 14 times higher than the FOR for non-medical reasons, using, respectively, 8.0 and 8.4
oocytes per cycle. Finally, 12 countries recorded storage following OtC and only 7 recorded the number of grafted frozen/thawed tissues.
LIMITATIONS, REASONS FOR CAUTION: Not all countries have data regarding OoC collection, and some data came from voluntary
collaborating centres, rather than a national authority or register. Furthermore, the data related to use of OoC were not included for two
major players in the field, Italy and Spain, where numbers were conflated for medical and non-medical reasons. Finally, the number of cycles
started with no retrieval is not available. Data are even sparser for OtC.
WIDER IMPLICATIONS OF THE FINDINGS: There is a need for ART authorities and professional bodies to record precise data for
practice and use of OoC (and OtC), according to indications and usage, in order to reliably inform all stakeholders including women about
the efficiency of both methods. Furthermore, professional societies should establish professional standards for access to and use of OoC and
OtC, and give appropriate guidance to all involved.
STUDY FUNDING/COMPETING INTEREST(S): The study was supported by ESHRE. There are no conflicts of interest.
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Introduction
Oocyte cryopreservation (OoC) practice is increasing in Europe and
worldwide, and has been described as ‘women’s emancipation set in
stone’ (Homburg et al., 2009), especially since the advent of the more
efficient vitrification technique (Rienzi et al., 2010). It is of importance
to cancer patients, or any woman whose ovarian reserve is endan-
gered by a medical condition and/or its treatment. It can also be
important to women as a possible backup method or ‘insurance’ to
ameliorate their chances of conception when postponing pregnancy.
Furthermore, since the American Society for Reproductive Medicine
removed the ‘experimental label’ (Practice committee, 2013) and the
American Society of Clinical Oncology (Loren et al., 2013) updated its
guidelines with regard to both OoC and ovarian tissue cryopreserva-
tion (OtC), the practice has further grown worldwide.
A substantial number of oocytes are increasingly cryopreserved in
Europe, but only a few countries collect specific detailed data for this
purpose. The total number of ovarian tissue biopsies or ovaries cryo-
preserved in Europe is unknown, and it is difficult to accurately inform
women about the efficiency of the method, more specifically used
prior to cancer treatment in children or adolescents where stimulation
for OoC is not possible.
The medical indications for OoC are both general and ART specific.
General medical indications include mostly women whose cytotoxic
cancer treatment threatens their ovarian reserve or whose medical
pathology presents a similar danger. This is the case for severe endo-
metriosis (Somigliana et al., 2015), genetic disorders such as mosaic
Turner’s syndrome (Oktay et al., 2015), or severe Crohn’s disease
necessitating cytotoxic drugs. Such ‘medical indications’ for OoC avoid
ethical debates about the nature of the embryo and its cryopreserva-
tion (ESHRE Ethics and Law TF 1, 2001; ESHRE Ethics and Law TF 2,
2001), or legal disputes about embryo transfer when a couple breaks
up (Evans, ECHR, 2007). They may also present the advantage of
avoiding the need for egg donation when the recovered patient wishes
for a pregnancy at a later stage. Other medical but ART-specific indica-
tions accepted in current practice include emergency freezing in IVF
when sperm is not available on the day of oocyte retrieval, prevention
of ovarian hyperstimulation syndrome (OHSS) or accumulation of
oocytes either in cases of poor responders or to increase their avail-
ability for PGD (Argyle et al., 2016). A recent indication is also being
developed in transgender people, in case of female to male change
(Wallace et al., 2014; De Roo et al., 2016). Furthermore, improved effi-
ciency thanks to vitrification has led to the creation of donor egg banks
which simplifies the logistics of egg donation and avoids the need to
match donor’s and recipient’s cycles, and alleviates waiting lists (Cobo
et al., 2010).
In contrast, the other indication, variously labelled as ‘non-medical’,
‘social’ or ‘elective’ because of age-related loss of oocytes has led to
vigorous semantic debates. These debates include ethical issues, as
respect of women’s autonomy, as well as social concerns of equity
(ESHRE TF 18, 2012) and public funding. It is important to keep in
mind that medicine must do as little harm as possible, and pregnancy
at a later age involves more complications and costs. Indeed, the post-
ponement of first pregnancy in the late last century and the beginning
of this century is well documented (Mills et al., 2011), as are the many
socio-cultural reasons linked by scholars in social sciences to changes
in the female gender roles with better access to contraception, and
access to further education and career opportunities (Baldwin et al.,
2015). This is also described by women who are thinking of electively
cryopreserving oocytes (Stoop et al., 2011a,b), when they spend more
time in education aiming at a fulfilling career, and voice concerns of not
having yet met the appropriate future father of their wanted family. It
appears however, that both women, whatever their level of education
(Lucas et al., 2015), and professionals tend to underestimate age-
related fertility decline (Yu et al., 2016).
Vitrification and the possibility for women to ‘put eggs on ice’ effi-
ciently have made many press headlines, especially in the non-medical
context, but there are few specific national data, although collection
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has started or is planned in some countries. This uneven recording of
information reinforces the need for large databases about collection
and use of OoC, in order to assess whether OoC will prove to be a
panacea or a delusion (Lockwood, 2011). Indeed a recent review sum-
marizing the history, techniques, indications and outcome of OoC
stresses ‘the real need to monitor what is being done,…and the suc-
cess rates achieved’ (Argyle et al., 2016) and points out there is still a
need to obtain wider quantitative and qualitative information.
With regard to OtC, the technique has been used both for chil-
dren/adolescents (Wallace et al., 2016) and adults. In adults, there is
as yet no consensus as to which approach (OoC or OtC) is optimal,
although, with regard to the urgency of starting chemotherapy, timeli-
ness is often the decisive factor. Whilst the first attempt at autotrans-
plantation of frozen thawed ovarian tissue dates from 2001 (Oktay
et al., 2001), and the first live birth was published in 2004 (Donnez
et al., 2004), OtC nowadays allows a realistic chance of pregnancy
after gonadotoxic therapy, by orthotopic or heterotopic retransplanta-
tion of ovarian tissue stored before cancer treatment.
The purpose of the present study was to improve the general
knowledge of OoC and OtC rules and practice in Europe: first, to
obtain information on legal or professional codes of practice, indica-
tions, and reimbursement of the treatment, and second to collect data
on numbers of cycles performed and oocytes stored by indication and
by country.
Materials andMethods
A collaboration between two ESHRE groups, the Special Interest Group
for Socio Cultural Aspects of Infertility (SCAIF) and the European IVF
Monitoring (EIM) was started in 2014, with three members of each group
planning the study and its protocol, and designing a two part questionnaire
(see Supplementary Data). In the first part, we asked whether OoC was
submitted or not to a law or code of practice (COP), whether regulations
concerned or not women’s age, civil status, medical indications: serious
disease (woman, child-adolescent), other medical indication (poor ovarian
reserve, poor responders, OHSS risk, PGD/PGS) and egg donation. A
specific question concerned OoC authorization for non-medical indica-
tions, and if it was reimbursed or not. In the second part, we also asked for
both the number of cycles performed and oocytes retrieved in total and by
main indications since 2010. All ‘other’ medical indications were grouped
as a single item for simplicity. The survey was conducted during 2015, and
at the end of 2015, data were also sought about OtC through a short
second questionnaire (see Supplementary Data). The questionnaires were
sent to all national coordinators of the EIM register in early 2015, and to
members of the ESHRE committee of national representatives. Whenever
possible, further information was sought, such as in the UK where more
recent data were obtained through a Freedom of Information (FOI)
request, which according to the FOI Act 2000 compels public bodies to
answer a question within 3 weeks.
All data were sent to ESHRE Central office. A descriptive analysis was per-
formed after tabulation. Analysis comprised a description of national regula-
tions (questionnaire part 1) and then a description of the practice reported
by countries having filled out part 2. The number of cycles reported during
the whole period was described per year, allowing for a trend estimation.
However, several countries did not report data every year, either because
OoC was not practiced, or not recorded between 2010 and 2012.
Furthermore, the questionnaire was sent too early to get all data for the
year 2014. Thus, the detailed description by indication was performed on
the year 2013 where data were the most comprehensive.
Results
Overall, amongst the 34 countries contributing to EIM, the Part 1
questionnaire was completed in 27 countries, whilst Part 2 of the OoC
questionnaire was only completed in 17, and the OtC questionnaire in 12.
Regulatory background and funding
Regulations
The picture is far from homogeneous in Europe, and varies from strict
legislation forbidding non-medical indications to allowing both medical
and non-medical indications, mostly by not excluding the latter
(Table I). In 12 countries, no specific regulation for OoC existed, while
14 countries rely on a law (of which 6 have a COP) and 1 (Romania)
only on a COP. Many have a register for ART but, in 2015, there were
two national registers where the number of OoC cycles was available,
whilst four more are planned in the near future, such as in Denmark,
Italy, and the Netherlands during 2016, or France (2017). With regard
to the UK, aggregated data for 2013 were included in the most recent
annual report (HFEA Annual Results, www.hfea.gov.uk), but there are
no plans to present them more specifically according to indications in
the near future.
Criteria and conditions for freezing
Only seven countries specified a minimum or maximum age limit,
applying to both medical and non-medical indications in Belgium
(below 45 years), Denmark (<46 years), Germany (20–49 years) and
Spain (>18 years), whilst in France (18–42 years), Malta (25–42 years)
and Slovenia (<45 years), it applies to medical indications only as stor-
ing for non-medical reasons is either not practiced or not allowed
(Table I). Only three countries specifically forbid non-medical OoC,
Austria, France (except for egg donors with no children, since spring
2016) and Malta. Most other countries practicing non-medical freezing
do so in a context of the absence of specific law. Furthermore, the
rules for non-medical freezing may depend on a professional society
decision. In Denmark, cryopreserved oocytes may be kept initially for
5 years and the cryopreservation period is extendable for medical rea-
sons; moreover, oocytes can be donated to research, but not for
reproduction, with further written consent.
Funding
With regard to funding, OoC is free for medical reasons in 14 (just
over half) responding countries, either through direct state funding or
a compulsory insurance system such as in the Netherlands (Table I).
Non-medical OoC is never funded by any state system. The UK allows
cryopreservation for 10 years, renewable with further consent ‘if there
is a serious risk of permanent infertility’ up to the age of 55 years, and
is free in the National Health Service for medical reasons.
Number of cycles performed and oocytes
retrieved for OoC during 2010–2014
In total, 34 753 OoC cycles were reported during the 5-year-period
among 17 countries with available data, with a progressive annual
increase, except in 2014 where the report was incomplete (Table II).
During the period 2010–2013, this increase was partly due to an
increase in seven countries, (Belgium, Czech Republic, France,
Germany, Greece, UK and Ukraine) and new developments in five
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countries (Belarus, Finland, Hungary, Malta and Switzerland), whereas
the numbers were fluctuating in four countries (Estonia, Italy, Slovenia
and Spain). Data were too inconsistent to be presented for Romania.
It also can be noticed that the greatest user of OoC was Spain, with
fluctuating data during 2010–2013, followed by UK and France. In
2014, even with incomplete data available, there has been a significant
increase in Spain, UK and Ukraine.
Number of OoC cycles performed in 2013
according to indications
OoC was performed in all countries who had data for 2013 (n = 17)
(Table III). In six countries, including Finland, France and Spain, the
total number of OoC cycles performed was not accompanied by the
number of oocytes retrieved. The UK published specific data by indica-
tion for their annual report in 2011, but has since stopped. More
recent data were thus obtained through a FOI request.
A total of 9126 specific OoC cycles were performed in the 16 coun-
tries with available data, out of a total of 343 025 ART aspirations (or
2.7% of all aspirations), with Spain performing 61.6% of all. Indications
were reported for 8885 cycles (97.4%). Overall, 59.9% OoC specific
cycles were performed for egg donation, whilst the proportion of
cycles performed for serious disease, other medical indications and
non-medical reasons were respectively 10.9%, 16.1% and 13.1% of the
total number of OoC cycles.
Number of oocytes retrieved
The number of oocytes was very unevenly reported in 2013 by 14
countries (Table III). The total number (n = 23 655) was reported by
11 countries (9.1 per aspiration) and the number by indication by 13
countries, furthermore differing according to the four indications. For
instance, only Greece and the UK provided the fullest data for all indi-
cations, whilst only 5 countries reported this number for oocyte
......................... ......................................................... ....................................
.............................................................................................................................................................................................
Table I Regulations, indications, and funding for OoC in 2015 for 27 European countries.
Country Specific regulation ART register Indications for freezing Funding
General OoC* Age (years) Medical Non-medical Medical Non-medical
Austria Law Yes No No Yes Forbidden No No
Belarus No No No No Yes No No No
Belgium No Yes Yes <45 No No Yes No
Bulgaria No No No No Yes Yes No No
Czech Republic No Yes No No No No Yes No
Denmark Law Yes 2016 <46 Yes No Yes No
Estonia No No No No No No No No
Finland Law Yes No No No Yes Yes No
France Law/COP Yes 2017 18–42 Yes Forbidden** Yes No
Germany Law/COP Yes Yes 20–49 Yes Yes No No
Greece No No No No No No No No
Hungary Law Yes No No Yes No No No
Italy Law Yes 2016 No Yes Yes Yes No
Ireland No No No No No No Yes No
Lithuania No No No No No No No No
Malta Law/COP Yes No 25–42 Yes Forbidden Yes No
Netherlands Law/COP No 2016 No Yes Yes Yes No
Norway Law Yes No No Yes No Yes No
Romania COP Yes No No No No No No
Russia No No No No Yes No No No
Slovakia No No No No No No No No
Slovenia Law No No <45 Yes No Yes No
Spain Law Yes No >18 No No Yes No
Sweden No Yes No No No No Yes No
Switzerland Law/COP Yes No No No No No No
UK Law/COP Yes No No No No Yes No
Ukraine No No No No Yes Yes No No
OoC, oocyte cryopreservation; COP, code of practice.
*Dates later than 2015 mean a specific registry is planned (putative date in italics).
**Except for childless egg donors who may self cryo-preserve some oocytes since 2016.
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donation (OD), 6 for serious disease, 10 for other medical indications
and 6 for non-medical indication. Unfortunately, Spain, a major player
in the field of OoC for OD started to record the number of oocytes
retrieved in OD cycles only in 2014. Thus, in this restricted and
uneven sample, the highest average yield of oocytes was found in case
of OD (10.4; SD 2.3), followed by serious disease (8.3; 1.3), non-
medical (7.6; 0.4) and ‘other medical’ ART indications (5.9; 3.3).
Use of cryopreserved oocytes
These data were too poorly reported to be presented in a table. For
medical indications, 13 countries reported 773 cycles, of which 10
included the number of thawed oocytes (n = 3823). With regard to
non-medical OoC use, only four countries reported 53 cycles, of
which three reported the use of 365 oocytes. Moreover, Spain
reported medical and non-medical indications together.
Storage and use of ovarian tissue
While 24 questionnaires were returned, only 12 countries recorded
storage of ovarian tissue. Data were unavailable in 7 countries and
these techniques were not practiced in 5. By the end of 2014,
Germany, France and Denmark had recorded the highest number of
stored ovarian tissue samples between 2010 and 2014 (Table IV).
With regard to OtC use, only 10 countries had data. During 2013, the
year with most complete data, the total number of samples stored and
samples used were, respectively, 1055 and 52.
Discussion
Data quality
The quality of data is very variable according to countries. Indeed,
whilst the EIM group has added a question concerning the use of
cryopreserved oocytes in ART cycles (Kupka et al., 2016), only
some countries have started recording data in professional national
registers, mostly as summaries. Furthermore, until recently, this was
mostly in the context of egg donation, such as in Spain, or of spare
oocytes from ART cycles when the Italian law was restrictive and
banned embryo freezing (Benagiano and Gianaroli, 2004). On the
whole, we had good data for 15 out 17 countries on numbers of
specific OoC cycles performed. After Spain, the UK, France, Italy,
Czech Republic and Belgium are also major players in the field.
Spain, however, performed more than 60% of all OoC cycles
reported in 2013, and the next important player in the field, France,
performed 8.7% of cycles.
However, data on the number of oocytes retrieved according to
indications were incomplete. It is therefore impossible to speculate on
the different yields of oocytes per cycle and per indication, although
fuller data, especially from Spain in the case of OD, should enable this
in the near future.
With regard to OtC, the major player is Germany with the highest
number of biopsies and grafts of all reported, performed between
2010 and 2014, followed by France (in the period 2010–2013), but
data were not complete or not available nationally in some countries
such as the UK where the practice is patchy (Davies, personal commu-
nication, 2016).
What can be inferred from the data for OoC
and OtC?
Whilst the data are not full or exhaustive, this study is the first to pre-
sent a set of OoC data for a large number of European countries. We
collected 9126 OoC aspirations from 17 countries in 2013, represent-
ing around 2.3% of all ART aspirations, yielding a total number of
23655 oocytes cryopreserved. This activity has also been growing
over the last 5 years.
The total number of OtC performed in 12 countries in 2013 can
only be compared as a whole with the 9126 OoC cycles for the same
year. Different countries emphasize the use of either method, but
some groups, such as the network FertiProtekt in German-speaking
countries (Germany, Austria, Switzerland) (FertiPROTEKT, 2016)
have elected to concentrate on OtC. This group, following the inter-
national Guidelines of the American Society of Clinical Oncology
(ASCO), recommends that all women up to the age of 40 years who
undergo gonadotoxic therapy should be counselled about fertility pre-
serving techniques by specialized physicians (von Wolff et al., 2011).
Data collection in this network is now internet based and can summar-
ize activities from more than 140 units of reproductive medicine, with
a recent publication including the results of 95 orthotopic transplanta-
tions of ovarian tissue after cytotoxic treatment (Van der Ven et al.,
2016). FertiProtekt represents a valuable model, together with the
case of Denmark, which also performs a large number, especially taking
into account the small size of this country population.
........................................................................................
Table II OoC cycles in 17 participating countries during
5 years.
Countries 2010 2011 2012 2013 2014**
Belarus NA 0 NA 3 NA
Belgium 10 49 310 386 NA
Czech Rep 68 220 344 471 202
Estonia 1 6 0 4 8
Finland NA NA NA 23 NA
France NA NA 451 798 NA
Germany 120 130 141 235 227
Greece* 8 9 10 34 34
Hungary* NA NA 2 5 2
Italy 286 554 415 477 358
Malta 0 0 NA 41 20
Romania NA NA NA NA NA
Slovenia 9 18 14 16 27
Spain ND 5612 6452 5620 6670
Switzerland NA NA NA 48 NA
UK 332 458 593 810 1063
Ukraine 11 27 91 155 265
Total:17 845 7083 8823 9126 8876
NA, not available.
*Greece and Hungary: data on OoC from six and five centres, respectively.
**Incomplete data at the end of the study.
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Reflections from the mosaic of policies
Legislation, professional codes and access are more of a patchwork
than uniform in Europe. In several countries, availability of OoC is only
for the various medical reasons outlined, and in all countries public
funding is reserved for such indications. It has been argued, however,
that the margin between medical and non-medical indications may be
blurred (ESHRE TF Ethics and law 15, 2008), and it is necessary to fur-
ther refine ‘medical’ indications, especially in the case of poor ovarian
reserve, generally considered a disease before 40 years of age and not
afterwards. It appears that until now the definition of ‘non-medical’,
sometimes called ‘social’ is made by exclusion, an important distinc-
tion, as no country provides public funding for this. Worse, there is no
general agreement for what constitutes a genuine medical indication,
as exemplified by the case of a young woman who was refused state
funding in the UK after chemotherapy for severe ulcerative colitis
severely endangered her reproductive future (Mc Donagh, 2014). The
distinction between medical and non-medical indications is relevant to
all countries, but access to the technique may be impeded by funding
even if the law itself is open to all possibilities. For instance, in the UK,
ART law has enabled access for single women and same sex couples
since 1990, (HFE Act 1990, revised 2008) and all indications for OoC
are allowed, but funding varies between regions even for medical rea-
sons, making access subject to regional decisions. This disagrees with
the National Institute for Clinical Excellence (NICE) recommendations
of three cycles for all patients (NICE, 2013). The Human Fertilisation
and Embryology Authority register has full coverage of ART cycles
nationally, but there are no separate national data on provisions in can-
cer patients as yet (Davies, 2016, personal communication). In France,
access to ART is restricted to medical indications (infertility or serious
risk of disease transmission) and has public funding nationally.
However, a recent modification was passed in order to promote gam-
ete donation because of an important lack of donors who were required
to already have children (Décret no 2015-1281 du 13 octobre 2015).
This decree allows young women without children to give eggs but
also implies that they have to be offered self-freezing of a number of
oocytes according to the available number given to others (Arrêté
du 24 décembre 2015 pris en application de l’article L. 2141–1 du
code de la santé publique). This makes a new exception allowing a
non-medical indication for OoC. Finally, some women are already
travelling outside their own country for elective ‘social’ freezing, another
form of cross-border reproductive care, in order to obtain this possible
insurance on their reproductive future, as the practice may be illegal at
home (Shenfield et al., 2010), especially if there are no medical indica-
tions warranting state funding. This applies to French women going to
Belgium (Stoop, personal communication, 2016), Spain or the UK, and is
another example of women exercising their autonomy in reproductive
choices or out of necessity (ESHRE TF ethics and law 15, 2008).
The importance of terminology
The terminology for non-medical OoC has been discussed widely. Some
authors proposed the terms ‘social’ (Mertes and Pennings, 2011), or ‘elective
cryopreservation to defer childbearing’ (ASRM practice committee, 2013),
.......................................................... ...............................................................................................................
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Table III General data on OoC practice in Europe, year 2013 (total 17 countries).















Belarus 2000 3 7 0/0 0/0 3/7 0/0
Belgium 19 590 386 3750 NA NA NA 366/2698
Czech Rep 18 574 471 5799 169/2178 NA 302/451 NA
Estonia 1836 4 31 0/0 0/0 2/23 2/8
Finland 4861 23 NA NA NA NA NA
France 62 235 798 NA NA 324/NA 474/NA 0/0
Germany 56 075 235 1350 NA NA NA NA
Greece NA 34 203 2/14 10/35 8/105 7/33
Hungarya 3535 5 36 0/0 NA 4/27 NA
Italy 50 174 477 3689 0/0 152/1456 296/1999 29/234
Malta 100 41 NA 0/0 0/0 41/NA NA
Romania 2156 NA NA 45/240 NA NA NA
Slovenia 3668 16 210 0/0 9/135 7/75 0/0
Spain 54 129 5620 NA 4853/NA 262/1970 8/60 497/3738
Switzerland 4964 48 NA NA 41/NA NA 7/NA
UK 46 421 810 7042 118/1099 165/1366 270/2462 257/2115
Ukraine 12 707 155 1538 136/1354 3/21 16/163 0/0
Total: 17 343 025 9126 23 655 5323/4885 966/4983 1431/5372 1165/8826
Malta data represent number of patients and not cycles.
OD, oocyte donation.
aHungary: data on OoC from five centres only.
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preferring to point out the inevitable biology of ‘age-related fertility
decline’ for women. In this aspect, the proposition of freezing for ‘antici-
pated gamete exhaustion’ (Stoop et al., 2015) stresses the biological and
preventative nature of this deliberate step taken by women against the
ills of nature (Stoop et al., 2014). Whatever the terminology, and in
both ‘Oocyte Cryopreservation for age related fertility loss’ (Dondorp
and De Wert, 2009; Ethics and law TF 15, 2008) and for medical rea-
sons, accurate data are relevant to women, practitioners and policy-
makers alike.
Conclusion
This study is the first presenting the conditions for storage and use,
and available data for OoC cycles and number of cryopreserved
oocytes, as well as OtC in most European countries, and means to be
a trigger and motivator to continue collection of these data prospect-
ively. It was found that, for the time being at least, equitable access to
OoC for women with medical indications is patchy in Europe, and that
there is no funding for age-related non-medical reasons. Indeed in our
data, the main reason for storage was for use in egg donation, with
similar numbers of cycles for medical indications, ART cycles and non-
medical reasons. The practice of non-medical OoC still raises a lot of
ethical and social–cultural issues, including access (Mertes and
Pennings, 2012), public policy for child care enabling women to have
children when their fertility is optimal, and education of young women
(and men) about the natural decline of ovarian reserve with age
(Stoop et al., 2014). Information must also point out the lower ART
efficiency after the age of 35 years (Cobo et al., 2016). The development
of non-medical indications requires forward thinking from all stake-
holders, such as healthy women thinking about what has been portrayed
as a possible insurance of their reproductive future, but does not carry
with it any certainty for success. Accurate information is paramount,
whether for patients as well as patients’ organizations and policy-
makers. A website with information can be a useful tool (Avraham et al.,
2014). Most importantly, the choice made by all stakeholders should be
backed up by verifiable information supported by data from profes-
sionals (Bastings et al., 2014), and professional societies.
ESHRE could be one of the major players in this process, with the
possibility to inform all stakeholders about the reality of the chances of
having a child born after OoC (and/or OtC), and a better appraisal of
efficiency, as OoC (and OtC) cannot be more than a partial insurance
against age-related fertility decline, varying in efficiency with indications
and age. With an increase of reliable data, ART professionals should
hopefully be able to better assess objectively the efficiency of this
method of fertility preservation so that women and funding bodies
may make an informed decision about using it as a back-up to natural
fertility when circumstances demand it.
Supplementary data
Supplementary data are available at Human Reproduction Open.
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Table IV Number of OtC and ovarian graft procedures




2013 2010–2014 2013 2010–2014
Austria 33 147 0 1
Belgium 103 624 8 23
Denmark 65 346 14 34
Estonia 8 38 NA 0
Finland 10 57 0 4
France 277 1096 10 29*
Germany 396 1499 16** 69**
Italy 98 399 1 11
Netherlands 13 56 0 5***
Norway* 13 100 0 3
Slovenia 1 14 0 0
Switzerland 38 98 3 6
Total 1055 4474 52 185
*2014 data not included.
**Data from one centre only.
***Data from 2012 only.
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SUPPLEMENTARY DATA





Is there a specific national regulation for OoC□No;□ Yes
• If yes, from:□ statutory authority;□ professional society (name:……)
• If from statutory authority, is there :□ a law;□ a code of practice;□both
• Other: please specify:
Are there any criteria for freezing:□No;□ Yes; if yes, specify:
• Woman’s age:□No;□ Yes; if Yes, specify: from□□ to□□
• Civil status: □ No criteria; □ Married/ in relationship;□ single
• □Medical indications
□ Serious disease of woman
□ Serious disease of adolescent
□ Predicted poor ovarian reserve/poor responders
□OHSS risk
□ For PGD/PGS, other reason (specify)
□ Egg donation
□ Authorized for non-medical indications
Funding available:
Medical reasons:□free/state;□ personal insurance;□No;□ retrieval □storage
Non-medical reasons:□free/state;□ personal insurance;□No;□ retrieval;□storage
Does the regulation cover other aspects?
• Method of cryopreservation:□ vitrification;□ slow freezing;□ both ;□ no
• Type of straws:□open;□ closed;□ both ;□no
• Patients’ counselling:□No;□ Yes
Is there a national ART register (tick box) or separate OoC register (tick box)
□Already in place: since (year) /____/____/____/____/
□Planned: For when? (year): /____/____/____/____/
□ If exists or planned:□Based on individual data;□ Based on data summaries□No national register, clinic data only ;
.............................................................................................................................................................................................
OoC data in your country
General numbers 2010 2011 2012 2013 2014
Total number of aspirations in the country (IVF+OD+ PGD) Cycles
Aspirations for OoC Cycles
Total number cryopreserved oocytes Oocytes
Vitrified oocytes Oocytes
‘Slow freeze’ oocytes Oocytes





(Other) medical reasons* (describe at the bottom of the page) Cycles
Oocytes
Non-medical reasons (social freezing) Cycles
Oocytes





*If unavailable numbers for specific medical reasons, put the overall number of medical reasons in (other) medical reasons.
Note: If no data in specific years, please put N/A (not applicable) in the corresponding column.
.............................................................................................................................................................................................
Ovarian tissue cryopreservation (OtC) data in your country
General numbers 2010 2011 2012 2013 2014
Ovarian tissue biopsy/cortex/whole ovary cryopreservation
Ovarian tissue graft procedures
Notes: If no data in specific years, please put N/A (not applicable) in the corresponding column.
If ‘Not practiced’: please put NP.
